paper
survey
import
insight
molecular
evolut
contribut
evolutionari
medicin
includ
phage
therapi
cancer
biolog
helminth
manipul
host
immun
system
qualiti
control
gamet
pathogen
outbreak
molecular
evolut
help
revolution
understand
cancer
autoimmun
diseas
origin
spread
pathogenesi
emerg
diseas
suggest
new
therapi
illumin
mechan
reveal
histor
process
practic
therapeut
implic
much
accomplish
much
remain
done
phage
therapi
shortliv
success
patient
belgium
acquir
p
aeruginosa
infect
develop
necrot
pressur
sore
extend
hospit
follow
bowel
surgeri
jenn
et
al
evolutionari
medicin
increasingli
well
recogn
area
basic
research
medic
practic
support
grow
literatur
issu
journal
molecular
evolut
contribut
consist
point
evolutionari
approach
shed
use
light
medic
topic
introduc
focu
excit
recent
advanc
offer
opportun
interest
skill
analysi
molecular
evolut
advanc
includ
insight
phage
therapi
cancer
biolog
hostparasit
interact
reproduct
biolog
pathogen
outbreak
discuss
aim
scholarli
review
cover
major
contribut
space
limit
recent
review
avail
elsewher
treatment
could
bore
reader
instead
chosen
topic
find
excit
use
recent
refer
provid
entri
rapidli
expand
literatur
seek
broader
introduct
might
sampl
evolutionari
medicin
stearn
medzhitov
although
initi
develop
earli
twentieth
centuri
discoveri
widespread
use
antibiot
phage
therapi
reemerg
one
key
element
respons
widespread
evolut
antibiot
resist
mani
bacteri
pathogen
becom
therapi
choic
case
bacteri
strain
resist
avail
antibiot
threaten
critic
ill
patient
hospitalacquir
infect
phage
attack
eukaryot
cell
patient
induc
anaphylaxi
elicit
product
antiphag
antibodi
dampen
impact
without
necessarili
result
treatment
failur
follow
long
histori
success
human
eastern
europ
particularli
poland
georgia
recent
demonstr
efficaci
anim
model
phage
therapi
succeed
treat
two
case
pseudomona
aeruginosa
infect
belgium
us
current
focu
larg
scale
trial
franc
belgium
switzerland
aim
prevent
burn
infect
kakasi
panitsa
damag
septicemia
caus
p
aeruginosa
emerg
patient
went
coma
emerg
clearanc
administr
author
ml
purifi
phage
cocktail
administ
intraven
h
day
day
time
wound
directli
irrig
cocktail
everi
h
day
improv
dramat
blood
cultur
turn
neg
almost
immedi
temperatur
return
normal
day
blood
test
use
assess
infect
return
normal
rang
within
week
unfortun
patient
die
month
later
hospit
heart
failur
mediat
sepsi
caus
klebsiella
outcom
happier
patient
connecticut
chronic
multipleresist
p
aeruginosa
infect
aortic
dacron
graft
chan
et
al
case
therapeut
team
chose
clever
strategi
select
phage
target
efflux
pump
endow
bacterium
antibiot
resist
follow
phage
treatment
knock
efflux
pump
antibiot
treatment
infect
resolv
recur
team
gone
treat
seven
case
chan
per
comm
five
cystic
fibrosi
cf
two
noncf
bronchiectasi
type
copd
bronchi
damag
mucu
accumul
bacteria
grow
accumul
mucu
seven
case
treat
inhal
aerosol
seven
improv
observ
one
case
noncf
bronchiectasi
lung
infect
erad
two
case
cf
multipleresist
bacteri
infect
current
treat
phase
trial
phage
therapi
burn
victim
p
aeruginosa
infect
franc
belgium
reduc
bacteri
burden
rapidli
standard
care
compar
sulfadiazin
cream
jault
et
al
case
concentr
phage
lower
plan
specif
select
disabl
efflux
pump
bacteria
subsequ
shown
resist
low
dose
phage
also
suscept
antibiot
comparison
treatment
phage
therapi
alway
succeed
success
take
care
plan
appropri
target
current
best
deploy
infect
caus
multipleresist
bacteria
bacteria
evolv
defens
phage
famou
crispr
other
current
best
practic
involv
preliminari
stage
phage
librari
screen
identifi
strain
effect
specif
bacteria
bacteria
equal
suscept
phage
attack
mani
bacteria
could
evolv
defens
reaction
phage
therapi
thu
one
research
prioriti
identifi
molecular
marker
phage
bacteria
signal
capac
attack
resist
test
top
candid
vitro
anim
model
follow
phase
trial
human
therebi
develop
reliabl
overview
phage
therapi
use
second
research
prioriti
investig
whether
phage
safe
deploy
human
gut
without
compromis
function
essenti
microbiota
oral
administr
would
open
rang
recalcitr
infect
phage
therapi
potenti
seriou
side
effect
could
elimin
benefici
bacteria
gut
microbiota
detail
molecular
detect
work
requir
explor
balanc
cost
benefit
third
research
prioriti
conduct
largescal
molecular
screen
aim
match
natur
divers
phage
larg
unexplor
natur
suscept
pathogen
bacteria
could
produc
open
access
data
bank
therapeut
option
might
indic
tri
first
clean
water
suppli
improv
nutrit
antibiot
vaccin
caus
infecti
diseas
drop
lead
caus
mortal
develop
countri
mortal
rate
decreas
caus
major
demograph
shift
mani
peopl
surviv
older
age
older
group
noninfecti
caus
death
emerg
select
shadow
previous
shorter
lifespan
becam
increasingli
import
promin
among
caus
heart
diseas
dementia
cancer
corbett
et
al
everi
cancer
case
clonal
evolut
one
major
cancer
treatment
chemotherapi
elicit
evolut
resist
among
compet
clone
rapid
dramat
antibiot
resist
chemotherapi
kill
suscept
clone
favor
resist
clone
come
domin
set
metastas
kill
patient
treatment
fail
manag
chemotherapi
slow
evolutionari
respons
first
subject
section
cancer
biolog
risk
metastat
cancer
first
place
rel
recent
evolv
result
superfici
chang
deepli
root
biolog
part
answer
lie
surpris
connect
invas
placenta
risk
metastas
second
subject
section
identifi
genet
vulner
uniqu
cancer
cell
share
normal
cell
deriv
exploit
vulner
target
therapi
kill
cancer
cell
leav
normal
cell
unharm
evolutionari
histori
gene
duplic
produc
function
paralog
help
locat
appropri
target
third
subject
section
increas
risk
cancer
old
age
part
byproduct
allel
increas
fit
earlier
life
via
impact
juvenil
surviv
fecund
lifetim
reproduct
success
antagonist
pleiotropi
direct
molecular
evid
effect
exist
fourth
subject
section
cancer
origin
sequenc
mutat
mark
emerg
threat
multipl
metastas
harvest
singl
patient
sequenc
allow
us
reconstruct
phylogenet
histori
applic
molecular
phylogenet
becom
increasingli
common
yield
surpris
insight
insight
lend
hope
improv
detect
therapi
fifth
subject
section
set
clone
constitut
tumor
evolv
respons
chemotherapi
attempt
target
specif
molecular
mechan
resist
littl
success
divers
mechan
present
among
genet
differ
clone
chemotherapi
aim
one
mechan
simpli
allow
cell
use
mechan
increas
treat
maximum
dose
also
hasten
expans
resist
clone
reduc
competit
suscept
clone
insight
initi
explor
model
show
patient
surviv
could
increas
modul
chemotherapi
maintain
stabl
popul
sensit
clone
suppress
resist
clone
absenc
chemotherapi
gatenbi
et
al
result
later
confirm
model
specif
case
castrateresist
prostat
cancer
cunningham
et
al
approach
call
adapt
therapi
done
safe
cancer
whose
growth
follow
imag
method
essenti
know
tumor
burden
stabil
key
insight
although
evolut
resist
everi
current
avail
therapi
inevit
expans
resist
cell
delay
perhap
indefinit
intervent
base
understand
clonal
dynam
proofofprincipl
demonstr
model
system
includ
mice
gatenbi
et
al
cultur
human
breast
cancer
cell
silva
et
al
approach
move
phase
clinic
trial
gatenbi
per
comm
idea
placent
metastasi
might
relat
initi
prompt
casual
observ
speci
less
invas
placenta
ungul
fewer
metastat
cancer
solid
tumor
speci
invas
placenta
carnivor
primat
everi
cell
bodi
contain
genet
inform
need
carri
function
cell
stage
life
would
make
sens
organ
cell
invad
endometrium
implant
would
contain
adult
cell
could
reactiv
capac
metastat
cell
capabl
move
among
tissu
establish
new
environ
molecular
evid
indic
genet
network
deploy
placent
cancer
cell
ferretti
et
al
phylogenet
evid
suggest
invas
ancestr
state
eutheria
invas
involv
two
actor
fetal
cell
invad
matern
cell
resist
compar
evid
suggest
ancestr
state
fetal
invas
counter
matern
resist
stronger
ungul
carnivor
dsouza
wagner
role
play
evolv
chang
matern
resist
recent
receiv
experiment
support
studi
invas
human
bovin
cancer
placent
cell
lawn
bovin
human
endometri
cell
skin
fibroblast
type
bovin
cell
resist
invas
either
type
human
cell
moreov
gene
higher
express
human
bovin
fibroblast
identifi
knock
human
fibroblast
cell
resist
invas
significantli
strongli
work
suggest
permiss
stromal
tissu
invas
singl
charact
involv
invas
endometrium
fetal
cell
invas
variou
tissu
metastat
cell
gupta
et
al
thu
studi
stromal
invas
could
lead
antimetastat
therapi
synthet
lethal
exist
mutat
either
two
differ
gene
effect
mutat
caus
cell
death
effect
aris
two
gene
function
redund
cooper
pathway
therapeut
opportun
aris
mutat
one
gene
identifi
specif
cancer
block
express
gene
kill
cancer
cell
normal
cell
ashworth
approach
success
treat
patient
whose
cancer
associ
germlin
mutat
increas
risk
breast
ovarian
pancreat
prostat
cancer
ashworth
lord
evolutionari
twist
come
note
mani
pair
synthet
lethal
function
redund
paralog
one
research
opportun
skill
molecular
evolut
effici
identif
paralog
synthet
lethal
pair
platform
tailor
genom
analysi
cancer
would
enabl
broader
rang
individu
therapi
hu
per
comm
payoff
molecular
evolut
gener
would
come
deeper
understand
copi
duplic
gene
retain
function
germlin
mutat
gene
appear
maintain
modern
popul
fertil
benefit
smith
et
al
allel
improv
blastocyst
implant
reduc
infertil
also
decreas
lifespan
associ
increas
risk
varieti
cancer
kang
et
al
molecular
sleuth
also
suggest
signific
associ
cancer
risk
genet
adapt
cold
high
altitud
voskarid
expect
uncov
mani
associ
detect
pancreat
cancer
notori
speed
surviv
year
fact
gave
special
forc
result
one
first
phylogenet
analys
metastas
compar
metastas
pancreat
cancer
seven
individu
find
decad
elaps
initi
mutat
birth
nonmetastat
founder
cell
least
five
year
elaps
metastasi
began
patient
die
within
averag
anoth
year
yachida
et
al
insight
oncologist
much
longer
time
thought
detect
cancer
help
motiv
mani
subsequ
phylogenet
analys
metastas
one
issu
studi
seek
resolv
whether
metastas
spread
metastasi
metastasi
parallel
metastas
primari
tumor
simpli
observ
monophyli
metastas
distinguish
option
requir
ultradeep
sequenc
identifi
complet
phylogeni
clone
within
primari
tumor
hong
et
al
later
studi
demonstr
fact
metastas
origin
differ
lineag
within
primari
tumor
confirm
metastat
lineag
aris
earli
within
primari
tumor
often
long
diagnosi
focus
attent
identifi
driver
mutat
origin
earli
show
sequenc
driver
mutat
aris
infer
phylogeni
thu
inform
strategi
target
therapi
zhao
et
al
clear
harvest
insight
cancer
biolog
molecular
phylogenet
fruit
naxerova
jain
yet
complet
hygien
hypothesi
posit
autoimmun
diseas
increas
preval
civil
clean
environ
suppress
infecti
diseas
two
pattern
stimul
first
tempor
correl
develop
countri
strike
increas
incid
autoimmun
diseas
decreas
infecti
diseas
twentieth
centuri
second
lack
autoimmun
diseas
tropic
countri
helminth
infect
widespread
two
pattern
one
time
space
suggest
idea
clean
environ
unintend
side
effect
perturb
microbiota
serious
immun
patholog
result
initi
helminth
prime
suspect
life
histori
suggest
highli
develop
capac
manipul
immun
respons
host
helminth
suffer
huge
mortal
loss
transmiss
among
host
loss
balanc
long
persist
high
fecund
establish
host
function
greatli
aid
abil
manipul
host
immun
system
pathogen
parasit
symbiont
also
experienc
major
challeng
human
host
acquir
domest
via
agricultur
industri
epidemiolog
revolut
seri
rapid
cultur
chang
left
biolog
gener
microbiota
particular
mismatch
current
environ
rook
remov
element
microbiota
helminth
result
immun
patholog
identifi
helminth
present
yield
clue
therapi
autoimmun
diseas
includ
type
diabet
variou
irrit
bowel
syndrom
crohn
diseas
ulcer
coliti
celiac
diseas
multipl
sclerosi
allergi
asthma
other
therapi
sore
need
physician
usual
abl
treat
symptom
caus
autoimmun
diseas
caus
great
suffer
kill
helminth
interact
directli
host
produc
protein
glycan
exosom
contain
mirna
interact
indirectli
promot
growth
bacteria
produc
short
chain
fatti
acid
maintain
popul
immun
cell
includ
treg
coakley
et
al
helminth
product
interact
molecul
use
coordin
commun
within
immun
system
interleukin
cytokin
helminth
live
gut
use
pathway
suppress
inflammatori
respons
particular
sourc
inspir
potenti
therapi
inflammatori
bowel
diseas
varyani
et
al
attempt
use
live
worm
cocktail
worm
egg
therapi
mix
result
prompt
attent
shift
develop
worminspir
drug
administ
control
dose
list
molecul
excret
secret
es
helminth
long
contain
mani
protein
protein
make
problemat
drug
antigen
elicit
immun
respons
worminspir
drugdevelop
therefor
focus
lowmolecular
weight
es
compon
artifici
small
molecul
mimic
activ
site
protein
kahl
et
al
advanc
proteom
develop
bioreactor
modul
human
gutonachip
model
acceler
progress
potenti
drug
yet
clinic
trial
comprehens
understand
coevolut
molecular
interact
helminth
host
would
provid
mani
insight
guid
develop
therapi
increas
preval
difficulttotreat
diseas
civil
mammalian
egg
sperm
differ
dramat
biolog
human
femal
ovari
form
fetu
third
month
stock
million
primari
oocyt
arrest
prophas
meiosi
process
oocyt
atresia
start
decreas
number
roughli
million
left
birth
thousand
young
woman
start
menstruat
menarch
oocyt
start
recruit
ovul
kerr
et
al
process
continu
less
dramat
pace
number
follicl
drop
endocrin
threshold
need
sustain
ovul
menstruat
woman
enter
menopaus
thu
women
start
finit
number
primari
oocyt
steadili
lose
replac
may
possibl
kerr
et
al
run
contrast
sperm
produc
test
puberti
spermatogonia
continu
undergo
mitosi
meiosi
throughout
life
produc
million
sperm
per
day
concentr
male
sex
hormon
start
declin
age
sperm
product
decreas
usual
ceas
complet
death
strike
genet
differ
oocyt
sperm
number
mitos
initi
format
gonad
product
gamet
oocyt
hundr
sperm
mitosi
opportun
mutat
differ
development
histori
help
explain
number
mutat
enter
human
popul
men
roughli
five
time
number
enter
women
contribut
men
increas
frequenc
age
father
crow
crow
b
femal
mammal
invest
time
energi
offspr
male
could
therefor
expect
evolv
sophist
method
qualiti
control
offspr
male
kozlowski
stearn
allow
oocyt
minim
opportun
mutat
first
basic
featur
qualiti
control
control
qualiti
oocyt
fertil
implant
becom
fetus
top
prioriti
evolutionari
design
femal
reproduct
tract
suggest
oocyt
atresia
function
elimin
genet
defect
oocyt
stearn
ebert
mechan
involv
discov
one
dnadamageinduc
apoptosi
rest
oocyt
mediat
member
famili
tuppi
et
al
oocyt
death
also
trigger
defect
synapsi
recombin
chromosom
meiosi
produc
doubl
strand
break
also
induc
apoptosi
qiao
et
al
know
mani
defect
oocyt
elimin
mechan
involv
yet
good
estim
averag
qualiti
random
oocyt
select
age
random
femal
life
thu
especi
given
possibl
replac
yet
provid
reliabl
answer
question
oocyt
atresia
improv
egg
qualiti
evid
qualiti
control
deterior
age
percentag
trisomi
recogn
pregnanc
increas
age
age
strike
acceler
incid
start
age
crow
atresia
reduc
rate
damag
increas
matern
age
clearli
intrigu
research
opportun
signific
therapeut
implic
agerel
molecular
popul
genet
oocyt
studi
agerel
mechan
mediat
qualiti
need
direct
molecular
evid
idea
genet
qualiti
egg
improv
atresia
human
primat
menopaus
follow
signific
period
postreproduct
surviv
organ
reproduc
die
strike
question
stimul
sever
hypothes
menopaus
evolv
one
grandmoth
hypothesi
see
menopaus
adapt
allow
age
femal
gain
fit
help
offspr
rear
grandchildren
would
anoth
child
age
might
abl
care
properli
independ
hawk
et
al
grandmoth
hypothesi
stimul
substanti
literatur
support
overal
evid
mix
eg
strassmann
garrard
second
hypothesi
view
menopaus
adapt
byproduct
qualiti
control
end
result
final
run
oocyt
subject
continu
atresia
stearn
ebert
third
hypothesi
combin
first
two
view
postreproduct
lifespan
human
femal
consequ
decreas
mortal
rate
selfdomest
allow
surviv
age
run
oocyt
filter
qualiti
control
point
evolut
make
use
presenc
older
femal
adapt
behavior
grandmoth
ellison
otting
possibl
caus
includ
impact
femal
mediat
intralocu
crosssex
effect
origin
select
male
whose
reproduct
abil
continu
greater
age
femal
stearn
et
al
investig
molecular
popul
biolog
oocyt
agedepend
mechan
control
qualiti
discrimin
among
hypothesesthat
requir
casecontrol
studi
lifetim
reproduct
successit
provid
relev
inform
advanc
discuss
constrain
rang
plausibl
idea
molecular
phylogenet
studi
ancestr
host
postemerg
evolut
human
pathogen
rich
field
inquiri
sever
decad
provid
increasingli
accur
answer
key
questionswher
come
anim
host
toler
chang
adapt
human
studi
yield
basic
insight
support
prevent
treatment
literatur
larg
mani
review
avail
discuss
strike
insight
recent
evolut
import
pathogen
current
epidem
cholera
yemen
produc
million
suspect
case
caus
two
thousand
death
almekhlafi
molecular
phylogenet
reveal
cholera
lineag
emerg
yemen
origin
south
asia
earlier
caus
outbreak
east
africa
importantli
lineag
suscept
sever
antibiot
use
treat
cholera
weill
et
al
critic
piec
evid
lend
confid
strategi
deploy
antibiot
without
seriou
concern
genet
variat
resist
soon
destroy
efficaci
tuberculosi
caus
human
death
infecti
diseas
origin
thought
human
acquir
tb
domest
anim
neolith
wholegenom
analys
suggest
human
transmit
tb
livestock
period
multipl
hostjump
may
occur
among
human
wild
anim
estim
time
tb
enter
human
rang
year
strike
degre
uncertainti
could
resolv
analyz
ancient
mycobacterium
genom
phylogenom
provid
use
insight
evolut
geograph
distribut
drug
resist
gagneux
interestingli
tb
appear
enter
nativ
american
popul
prior
european
colon
via
transmiss
seal
sea
lion
may
carri
across
ocean
european
voyag
cross
atlant
pacif
bo
et
al
ebola
viru
first
identifi
caus
agent
outbreak
kikwit
zair
follow
outbreak
largest
occur
guinea
liberia
sierra
leon
recent
continu
write
northeastern
democrat
republ
congo
case
fatal
rate
rang
basic
reproduct
number
r
number
new
case
origin
transmiss
patientha
ebola
strikingli
deadli
moder
transmiss
diseas
first
case
recent
west
african
outbreak
caus
case
death
duda
et
al
occur
late
decemb
guinea
appear
move
fairli
recent
central
africa
holm
et
al
molecular
phylogeographi
practic
real
time
allow
detail
reconstruct
origin
spread
knowledg
quit
help
deal
futur
outbreak
duda
et
al
influenza
pandem
infect
million
peopl
kill
million
appear
origin
shortli
human
hemagglutinin
variant
viru
recombin
avian
neuraminidas
variant
viru
worobey
et
al
emerg
geograph
locat
yet
locat
spread
simultan
across
europ
asia
north
america
taubenberg
moren
recoveri
sequenc
addit
intact
viral
genom
illumin
origin
spread
recent
great
pandem
repeat
perform
would
catastroph
human
immunodefici
viru
hiv
subject
intens
phylogenet
phylogeograph
scrutini
chimpanze
origin
host
major
caus
acquir
immun
defici
syndrom
aid
pathogen
chimpanze
four
lineag
jump
human
one
two
transmiss
may
via
gorilla
close
rel
simian
immunodefici
virus
siv
infect
speci
monkey
without
appar
pathogenesi
viru
lineag
caus
aid
pandem
probabl
enter
human
extrem
southeast
corner
cameroon
sharp
hahn
hunter
butcher
ape
detail
studi
genom
isol
sampl
shown
viru
circul
north
america
earli
arriv
new
york
citi
caribbean
worobey
et
al
zika
isol
primat
uganda
mosquitoborn
flaviviru
whose
human
infect
mostli
africa
asia
formerli
thought
sporad
mild
selflimit
emerg
yap
island
micronesia
confirm
case
infect
popul
mani
case
asymptomat
next
outbreak
case
peopl
infect
french
polynesia
case
link
syndrom
sever
neuropatholog
autoimmun
diseas
phylogenet
analys
indic
arriv
brazil
quickli
spread
end
appear
least
countri
territori
america
link
microcephal
birth
defect
expans
acquir
particular
amino
acid
substitut
lineag
birth
defect
detect
substitut
combin
revers
genet
model
organ
provid
clue
transmiss
pathogenesi
liu
et
al
molecular
phylogenet
establish
bat
reservoir
mani
danger
emerg
viral
diseas
includ
rabi
ebola
marburg
hendra
nipah
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
cui
et
al
bat
toler
virus
virul
human
sever
answer
propos
bat
idiosyncrat
immun
respons
restrict
specif
viral
infect
long
evolutionari
experi
avoid
immunopatholog
via
toler
daili
flight
torpor
season
hibern
speci
produc
larg
variat
temperatur
metabol
rate
associ
evolv
differ
mechan
mediat
oxid
stress
mechan
manag
reactiv
oxygen
speci
allow
live
long
live
despit
expend
twice
much
energi
per
lifetim
nonvol
mammal
compar
size
may
help
toler
viral
infect
brook
dobson
clearli
clue
treat
virul
diseas
known
man
could
found
toler
mechan
bat
evolv
inform
molecular
evolut
contribut
decis
excit
insight
evolutionari
medicin
phage
therapi
cancer
biolog
parasit
manipul
immun
system
human
reproduct
biolog
pathogen
outbreak
contribut
far
exhaust
attent
invit
